Novel approaches for studying amyloidogenic peptides/proteins

Current Opinion in Pharmacology

Volumn 13, Issue 5, 2013, Pages 797-801

  Beeg, Marten ^a   Diomede, Luisa ^a   Stravalaci, Matteo ^a   Salmona, Mario ^a   Gobbi, Marco ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; EPIGALLOCATECHIN GALLATE; IMMUNOGLOBULIN LIGHT CHAIN;

ALZHEIMER DISEASE; AMYLOIDOSIS; ARTICLE; BIOSENSOR; CAENORHABDITIS ELEGANS; DRUG SCREENING; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNOASSAY; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN FOLDING; QUARTZ CRYSTAL MICROBALANCE; SURFACE PLASMON RESONANCE; TRANSGENIC ORGANISM;

AMYLOIDOGENIC PROTEINS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; HUMANS; SURFACE PLASMON RESONANCE;

EID: 84892992289     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2013.05.010     Document Type: Review

References (45)

1. Merlini G, Seldin DC, Gertz MA: Amyloidosis: pathogenesis and new therapeutic options. J Clin Oncol 2011, 29: 1924-1933.
2. Chiti F, Dobson CM: Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006, 75: 333-366. (Pubitemid 44118036)
3. Bemporad F, Chiti F: Protein misfolded oligomers: experimental approaches, mechanism of formation, and structure-toxicity relationships. Chem Biol 2012, 19: 315-327.
4. Benilova I, Karran E, De Strooper B: The toxic Ab oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 2012, 15: 349-357.
5. Pedersen JT, Heegaard NH: Analysis of protein aggregation in neurodegenerative disease. Anal Chem 2013 http://dx.doi.org/10.1021/ac400023c. Epub ahead of print.
6. Bruggink KA, Muller M, Kuiperij HB, Verbeek MM: Methods for analysis of amyloid-b aggregates. J Alzheimers Dis 2012, 28: 735-758.
7. Rich RL, Myszka DG: Higher-throughput, label-free, real-time molecular interaction analysis. Anal Biochem 2007, 361: 1-6. (Pubitemid 46026999)
8. Taylor M, Moore S, Mayes J, Parkin E, Beeg M, Canovi M, Gobbi M, Mann DM, Allsop D: Development of a proteolytically stable retro-inverso peptide inhibitor of b-amyloid oligomerization as a potential novel treatment for Alzheimer's disease. Biochemistry 2010, 49: 3261-3272.
9. Richter L, Munter LM, Ness J, Hildebrand PW, Dasari M, Unterreitmeier S, Bulic B, Beyermann M, Gust R, Reif B et al.: Amyloid-b 42 peptide (Ab42)-lowering compounds directly bind to Ab and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proc Natl Acad Sci U S A 2010, 107: 14597-14602.
10. Stravalaci M, Beeg M, Salmona M, Gobbi M: Use of surface plasmon resonance to study the elongation kinetics and the binding properties of the highly amyloidogenic Ab(1-42) peptide, synthesized by depsi-peptide technique. Biosens Bioelectron 2011, 26: 2772-2775.
11. Mourtas S, Canovi M, Zona C, Aurilia D, Niarakis A, La Ferla B, Salmona M, Nicotra F, Gobbi M, Antimisiaris SG: Curcumin-decorated nanoliposomes with very high affinity for amyloid- b1-42 peptide. Biomaterials 2011, 32: 1635-1645.
12. Amijee H, Bate C, Williams A, Virdee J, Jeggo R, Spanswick D, Scopes DI, Treherne JM, Mazzitelli S, Chawner R et al.: The N-methylated peptide SEN304 powerfully inhibits Ab(1-42) toxicity byperturbing oligomer formation. Biochemistry 2012, 51: 8338-8352.
13. Domanska K, Vanderhaegen S, Srinivasan V, Pardon E, Dupeux F, Marquez JA, Giorgetti S, Stoppini M, Wyns L, Bellotti V et al.: Atomic structure of a nanobody-trapped domain-swapped dimer of an amyloidogenic beta2-microglobulin variant. Proc Natl Acad Sci U S A 2011, 108: 1314-1319.
14. Buxbaum JN, Ye Z, Reixach N, Friske L, Levy C, Das P, Golde T, Masliah E, Roberts AR, Bartfai T: Transthyretin protects Alzheimer's mice from the behavioral and biochemical effects of Ab toxicity. Proc Natl Acad Sci U S A 2008, 105: 2681-2686. (Pubitemid 351520573)
15. Fluharty BR, Biasini E, Stravalaci M, Sclip A, Diomede L, Balducci C, La Vitola P, Messa M, Colombo L, Forloni G et al.: An N-terminal fragment of the prion protein binds to amyloid-b oligomers and inhibits their neurotoxicity in vivo. J Biol Chem 2013, 288: 7857-7866.
16. Lindhagen-Persson M, Brännström K, Vestling M, Steinitz M, Olofsson A: Amyloid-b oligomer specificity mediated by the IgM isotype - implications for a specific protective mechanism exerted by endogenous auto-antibodies. PLoS ONE 2010, 5:e13928.
17. Stravalaci M, Bastone A, Beeg M, Cagnotto A, Colombo L, Di Fede G, Tagliavini F, Cantu L, Del Favero E, Mazzanti M et al.: Specific recognition of biologically active amyloid-beta oligomers by a new surface plasmon resonance-based immunoassay and an in vivo assay in Caenorhabditis elegans. J Biol Chem 2012, 287: 27796-27805.
18. Cannon MJ, Williams AD, Wetzel R, Myszka DG: Kinetic analysis of b-amyloid fibril elongation. Anal Biochem 2004, 328: 67-75. (Pubitemid 38479619)
19. Ryu J, Joung HA, Kim MG, Park CB: Surface plasmon resonance analysis of Alzheimer's b-amyloid aggregation on a solid surface: from monomers to fully-grown fibrils. Anal Chem 2008, 80: 2400-2407. (Pubitemid 351499821)
20. Sohma Y, Taniguchi A, Yoshiya T, Chiyomori Y, Fukao F, Nakamura S, Skwarczynski M, Okada T, Ikeda K, Hayashi Y et al.: Click peptide: a novel O-acyl isopeptide method for peptide synthesis and chemical biology-oriented synthesis of amyloid b peptide analogues. J Pept Sci 2006, 12: 823-828. (Pubitemid 44941585)
21. Beeg M, Stravalaci M, Bastone A, Salmona M, Gobbi M: A modified protocol to prepare seed-free starting solutions of amyloid-b Ab(1-40) and Ab (1-42) from the corresponding depsipeptides. Anal Biochem 2011, 411: 297-299.
22. Di Fede G, Catania M, Morbin M, Giaccone G, Moro ML, Ghidoni R, Colombo L, Messa M, Cagnotto A, Romeo M et al.: Good gene, bad gene: new APP variant may be both. Prog Neurobiol 2012, 99: 281-292.
23. Buell AK, Dobson CM, Welland ME: Measuring the kinetics of amyloid fibril elongation using quartz crystal microbalances. Methods Mol Biol 2012, 849: 101-119.
24. Buell AK, Dhulesia A, White DA, Knowles TP, Dobson CM, Welland ME: Detailed analysis of the energy barriers for amyloid fibril growth. Angew Chem Int Ed Engl 2012, 51: 5247-5251.
25. Holtzman DM, Goate A, Kelly J, Sperling R: Mapping the road forward in Alzheimer's disease. Sci Transl Med 2011, 3:114ps148.
26. Campioni S, Mannini B, Zampagni M, Pensalfini A, Parrini C, Evangelisti E, Relini A, Stefani M, Dobson CM, Cecchi C et al.: A causative link between the structure of aberrant protein oligomers and their toxicity. Nat Chem Biol 2010, 6: 140-147.
27. Glabe CG: Structural classification of toxic amyloid oligomers. J Biol Chem 2008, 283: 29639-29643.
28. Esparza TJ, Zhao H, Cirrito JR, Cairns NJ, Bateman RJ, Holtzman DM, Brody DL: Amyloid-b oligomerization in Alzheimer dementia vs. high pathology controls. Ann Neurol 2012, 73: 104-119.
29. Wolozin B, Gabel C, Ferree A, Guillily M, Ebata A: Watching worms whither: modeling neurodegeneration in C. elegans. Prog Mol Biol Transl Sci 2011, 100: 499-514.
30. Kirstein-Miles J, Morimoto RI: Caenorhabditis elegans as a model system to study intercompartmental proteostasis: interrelation of mitochondrial function, longevity, and neurodegenerative diseases. Dev Dyn 2010, 239: 1529-1538.
31. Link CD: Invertebrate models of Alzheimer's disease. Genes Brain Behav 2005, 4: 147-156. (Pubitemid 40559141)
32. Link CD: C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease. Exp Gerontol 2006, 41: 1007-1013. (Pubitemid 44821699)
33. Wu Y, Cao Z, Klein WL, Luo Y: Heat shock treatment reduces b-amyloid toxicity in vivo by diminishing oligomers. Neurobiol Aging 2010, 31: 1055-1058.
34. Diomede L, Cassata G, Fiordaliso F, Salio M, Ami D, Natalello A, Doglia SM, De Luigi A, Salmona M: Tetracycline and its analogues protect Caenorhabditis elegans from beta amyloid- induced toxicity by targeting oligomers. Neurobiol Dis 2010, 40: 424-431.
35. Stoilova T, Colombo L, Forloni G, Tagliavini F, Salmona M: A new face for old antibiotics: tetracyclines in treatment of amyloidoses. J Med Chem 2013 http://dx.doi.org/10.1021/jm400161p. Epub ahead of print.
36. Di Fede G, Catania M, Morbin M, Rossi G, Suardi S, Mazzoleni G, Merlin M, Giovagnoli AR, Prioni S, Erbetta A et al.: A recessive mutation in the APP gene with dominant-negative effect on amyloidogenesis. Science 2009, 323: 1473-1477.
37. Zhang P, Fu X, Sawashita J, Yao J, Zhang B, Qian J, Tomozawa H, Mori M, Ando Y, Naiki H et al.: Mouse model to study human Ab2M amyloidosis: generation of a transgenic mouse with excessive expression of human b2-microglobulin. Amyloid 2010, 17: 50-62.
38. Shin JT, Ward JE, Collins PA, Dai M, Semigran HL, Semigran MJ, Seldin DC: Overexpression of human amyloidogenic light chains causes heart failure in embryonic zebrafish: a preliminary report. Amyloid 2012, 19: 191-196.
39. Diomede L, Soria C, Romeo M, Giorgetti S, Marchese L, Mangione PP, Porcari R, Zorzoli I, Salmona M, Bellotti V et al.: C. elegans expressing human b(2)-microglobulin: a novel model for studying the relationship between the molecular assembly and the toxic phenotype. PLoS ONE 2012, 7:e52314.
40. Giorgetti S, Raimondi S, Pagano K, Relini A, Bucciantini M, Corazza A, Fogolari F, Codutti L, Salmona M, Mangione P et al.: Effect of tetracyclines on the dynamics of formation and destructuration of b2-microglobulin amyloid fibrils. J Biol Chem 2011, 286: 2121-2131.
41. Jones D, Candido EP: Feeding is inhibited by sublethal concentrations of toxicants and by heat stress in the nematode Caenorhabditis elegans: relationship to the cellular stress response. J Exp Zool 1999, 284: 147-157. (Pubitemid 29311513)
42. Palladini G, Lavatelli F, Russo P, Perlini S, Perfetti V, Bosoni T, Obici L, Bradwell AR, D'Eril GM, Fogari R et al.: Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006, 107: 3854-3858. (Pubitemid 43726787)
43. Liao R, Jain M, Teller P, Connors LH, Ngoy S, Skinner M, Falk RH, Apstein CS: Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001, 104: 1594-1597. (Pubitemid 32947519)
44. Brenner DA, Jain M, Pimentel DR, Wang B, Connors LH, Skinner M, Apstein CS, Liao R: Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress. Circ Res 2004, 94: 1008-1010. (Pubitemid 38579694)
45. Shi J, Guan J, Jiang B, Brenner DA, Del Monte F, Ward JE, Connors LH, Sawyer DB, Semigran MJ, Macgillivray TE et al.: Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A 2010, 107: 4188-4193.